A Propensity-Matched Analysis between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection

Open Forum Infectious Diseases

Volumn 4, Issue 4, 2017, Pages

  Gentry, Chris A ^a   Giancola, Stephanie E ^a   Thind, Sharanjeet ^b   Kurdgelashvili, George ^b   Skrepnek, Grant H ^c   Williams, Riley J ^a  

^a Pharmacy Service

^b Oklahoma City Veterans Affair Medical Center   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Clostridium difficile; recurrence; vancomycin taper

Indexed keywords

EID: 85082524253     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofx235     Document Type: Article

References (21)

1. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-4.
2. Lessa FC, Winston LG, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:2369-70.
3. Richardson C, Kim P, Lee C, et al. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. Anaerobe 2015; 33:105-8.
4. Otter JA, Saber Y, French GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. Infect Control Hosp Epidemiol 2011; 32:687-99.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
6. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-15.
7. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rate, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
8. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
9. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
10. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55(Suppl 2):S93-103.
11. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults (review). Cochrane Database Syst Rev 2017; 3:CD004610.
12. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867-8.
13. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
14. United States Department of Veterans Affairs. National Center for Veterans Analysis and Statistics "Quickfacts". Available at: http://www1.va.gov/vetdata/docs/Quickfacts/Homepage-slideshow-06-04-16.pdf. Accessed 5 October 2016.
15. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res 2014; 49:1701-20.
16. Kociolek LK, Gerding DN. Clinical utility of laboratory detection of Clostridium difficile strain BI/NAP1/027. J Clin Microbiol 2016; 54:19-24.
17. Louie TJ, Miller MA, Mullane KM. Fidaxomicin versus vancomycin for C. difficile infection. N Engl J Med 2011; 364:422-31.
18. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-9.
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
20. Drekonja D, Reich J, Gezahegn S, et al. Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review Of The Evidence. Department of Veterans Affairs Health Services Research & Development Service ESP Project #09-009; 2014.
21. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376:305-17.